Seamlessly scaling cell & gene therapies

Introduction

Ori Biotech is a leader in the Cell & Gene Therapy (CGT) manufacturing technology based in London (UK) and New Jersey (US). They are developing a proprietary, bespoke and flexible manufacturing platform, to enable patient access to a new generation of personalized, life-saving treatments. By fully automating and standardizing CGT manufacturing in a closed platform, Ori Biotech offers seamless scaling from preclinical process development to commercial-scale manufacturing.

Ori Biotech’s experience

“We tried a couple of automated cell counters available on the market, but we were most impressed by the NucleoCounter® NC-202™ device for these key reasons:

1. Impressive consistency and reproducibility when taking multiple cell counts from one sample.
2. The software interface is extremely user friendly and easy to use. The NC-202™ is also significantly faster than other automated cell counters we tried.
3. Working with immune cell samples, often in aggregate culture means we routinely see cell count inaccuracy or inconsistency. However, the NC-202™ can accurately identify cell count and viability without a need to manually break the aggregates prior to cell counting.”